The Experts below are selected from a list of 2628 Experts worldwide ranked by ideXlab platform
Mahul B Amin - One of the best experts on this subject based on the ideXlab platform.
-
distribution of Cytokeratins and vimentin in adult renal neoplasms and normal renal tissue potential utility of a Cytokeratin Antibody panel in the differential diagnosis of renal tumors
The American Journal of Surgical Pathology, 2005Co-Authors: Brian Skinnider, Andrew L Folpe, Randolph A Hennigar, Cynthia Cohen, Pheroze Tamboli, Andrew T Young, Mariza De Peraltaventurina, Mahul B AminAbstract:Abstract:Adult renal epithelial neoplasms (RENs) comprise several distinct clinicopathologic entities with potential prognostic and therapeutic differences. Individual cases can show overlapping morphologic features, necessitating the use of ancillary methods. The purpose of this study was to determ
-
distribution of Cytokeratins and vimentin in adult renal neoplasms and normal renal tissue potential utility of a Cytokeratin Antibody panel in the differential diagnosis of renal tumors
The American Journal of Surgical Pathology, 2005Co-Authors: Brian Skinnider, Andrew L Folpe, Randolph A Hennigar, So Dug Lim, Cynthia Cohen, Pheroze Tamboli, Andrew T Young, Mariza De Peraltaventurina, Mahul B AminAbstract:Adult renal epithelial neoplasms (RENs) comprise several distinct clinicopathologic entities with potential prognostic and therapeutic differences. Individual cases can show overlapping morphologic features, necessitating the use of ancillary methods. The purpose of this study was to determine the diagnostic utility of Cytokeratin (CK) subtype expression pattern in a wide range of adult RENs. RENs (including clear cell [conventional] renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, renal oncocytoma, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), urothelial carcinoma, metanephric adenoma (MA), tubulocystic carcinoma (TC) (also known as low-grade collecting duct carcinoma), and mucinous tubular and spindle cell carcinoma) were immunostained for CK subtypes (CK5/CK6, 7, 8, 13, 14, 17, 18, 19, 20), high molecular weight CKs 1, 5, 10, 14 (HMWCK), and vimentin (Vim). The expression pattern of normal kidney was also examined and correlated with RENs. Although there is some overlap, subtypes of RENs show distinctive CK expression profiles that may be useful in several differential diagnostic settings. Clear cell RCCs typically showed a restricted expression pattern of CK8, CK18 and Vim. Papillary RCCs typically expressed CK7, CK8, CK18, CK19, and Vim and could be distinguished from MA (CK7-). Chromophobe RCCs were typically CK7+, CK8+, CK18+, and Vim-, and could be distinguished from oncocytomas (typically CK7-). In oncocytomas, nonspecific staining of unblocked endogenous biotin is a potentially significant diagnostic pitfall. CDC, RMC, and TC demonstrated similar CK expression profiles (with the exception of HMWCK expression limited to CDC), supporting a close relationship between these entities. A panel of CK5/CK6, CK17, and Vim may be helpful in distinguishing CDC (typically CK5/CK6-, CK17-, Vim+) and urothelial carcinoma (typically CK5/CK6+, CK17+, Vim-). In conclusion, CK expression patterns may be helpful in several differential diagnostic situations when dealing with adult RENs.
-
high molecular weight Cytokeratin Antibody clone 34βe12 a sensitive marker for differentiation of high grade invasive urothelial carcinoma from prostate cancer
Histopathology, 2003Co-Authors: M Varma, Meleri Morgan, Mahul B Amin, Sue Wozniak, Bharat JasaniAbstract:AIMS There is no well-established positive immunomarker for urothelial carcinoma. We evaluated the diagnostic utility of high molecular weight Cytokeratin (HMWCK) Antibody clone 34betaE12 in differentiating high-grade invasive urothelial carcinoma from prostate cancer. METHODS AND RESULTS Formalin-fixed paraffin-embedded sections from 28 cases of high-grade invasive urothelial carcinoma (20 not otherwise specified (UC-NOS), eight with glandular differentiation) and 20 cases of poorly differentiated prostate carcinoma were immunostained with a monoclonal Antibody to carcinoembryonic antigen (CEA), clone 85A12 and with HMWCK Antibody clone 34betaE12 after microwave pretreatment or protease 24 predigestion. All cases of UC-NOS expressed HMWCK on 34betaE12 immunostaining after microwaving or enzyme predigestion. Immunoreactivity was intense and diffuse in all the cases after microwave pretreatment, whilst with enzyme predigestion immunoreactivity was sometimes patchy with <50% tumour cells positive in 20% of cases. In comparison with 34betaE12, 85A12 was insensitive with 15% of UC-NOS cases totally CEA-negative and <50% tumour cell immunoreactivity in 60% of cases. Rare positive cells were present in two (10%) cases of prostate cancer with monoclonal anti-CEA and 34betaE12 on microwaved sections, but all the cases were HMWCK-negative using 34betaE12 on sections pretreated by enzyme digestion. CONCLUSIONS HMWCK Antibody clone 34betaE12, particularly when used with microwave heat retrieval, is a very sensitive positive marker for high-grade invasive urothelial carcinoma.
Guo Qiang Wang - One of the best experts on this subject based on the ideXlab platform.
-
• BRIEF REPORTS • Detection of lymph nodes micrometastases in Dukes ’ A and B colorectal cancer using anti-Cytokeratin antibodies AE1/AE3
2015Co-Authors: Zhiwei Zhou, Nick Rieger, Andrew Ruszkiewicz, Guo Qiang Wang, De-sen WanAbstract:AIM: To detect lymph nodes micrometastases and analyze its correlation with clinicopathological parameters in Dukes’ A and B colorectal cancer patients. METHODS: One hundred and fourteen patients with colorectal cancer (Dukes ’ A 16; Dukes ’ B 98) undergoing curative operation without histological lymph nodes metastases were studied between 2001 and 2003. A total of 2 481 lymph nodes were analyzed using monoclonal Cytokeratin Antibody AE1/AE3 (DAKO, Carpinteria, CA) for immunohist-ochemistry. RESULTS: In total, 33 (29%) patients were positive for cancer cell by immunohistochemistry. In 31 (94%) patients of them positive nodes showed single tumor cell or small groups of tumor cells; and tumor deposits measuring 0.
-
detection of lymph nodes micrometastases in dukes a and b colorectal cancer using anti Cytokeratin antibodies ae1 ae3
World Journal of Gastroenterology, 2005Co-Authors: Zhiwei Zhou, Nick Rieger, Andrew Ruszkiewicz, Guo Qiang WangAbstract:AIM: To detect lymph nodes micrometastases and analyze its correlation with clinicopathological parameters in Dukes’ A and B colorectal cancer patients. METHODS: One hundred and fourteen patients with colorectal cancer (Dukes’ A 16; Dukes’ B 98) undergoing curative operation without histological lymph nodes metastases were studied between 2001 and 2003. A total of 2 481 lymph nodes were analyzed using monoclonal Cytokeratin Antibody AE1/AE3 (DAKO, Carpinteria, CA) for immunohist-ochemistry. RESULTS: In total, 33 (29%) patients were positive for cancer cell by immunohistochemistry. In 31 (94%) patients of them positive nodes showed single tumor cell or small groups of tumor cells; and tumor deposits measuring 0.2 and 0.37 mm in diameter in another 2 (6%) patients. Micrometastases were mainly located in the subcapsular sinus or paracortical sinus. There was no correlation between the positive lymph nodes and gender, age, tumor site, tumor size, histological type, histological grade, invasion depth, Dukes’ staging and microsatellite instability (P>0.05). CONCLUSION: Our findings suggest that immunohist-ochemical technique using monoclonal Cytokeratin Antibody AE1/AE3 may be a sensitive and reliable method for detecting lymph nodes micrometastases in Dukes’ A and B colorectal cancer. The clinical significance of lymph nodes microme-tastases is still not confirmed.
Brian Skinnider - One of the best experts on this subject based on the ideXlab platform.
-
distribution of Cytokeratins and vimentin in adult renal neoplasms and normal renal tissue potential utility of a Cytokeratin Antibody panel in the differential diagnosis of renal tumors
The American Journal of Surgical Pathology, 2005Co-Authors: Brian Skinnider, Andrew L Folpe, Randolph A Hennigar, So Dug Lim, Cynthia Cohen, Pheroze Tamboli, Andrew T Young, Mariza De Peraltaventurina, Mahul B AminAbstract:Adult renal epithelial neoplasms (RENs) comprise several distinct clinicopathologic entities with potential prognostic and therapeutic differences. Individual cases can show overlapping morphologic features, necessitating the use of ancillary methods. The purpose of this study was to determine the diagnostic utility of Cytokeratin (CK) subtype expression pattern in a wide range of adult RENs. RENs (including clear cell [conventional] renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, renal oncocytoma, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), urothelial carcinoma, metanephric adenoma (MA), tubulocystic carcinoma (TC) (also known as low-grade collecting duct carcinoma), and mucinous tubular and spindle cell carcinoma) were immunostained for CK subtypes (CK5/CK6, 7, 8, 13, 14, 17, 18, 19, 20), high molecular weight CKs 1, 5, 10, 14 (HMWCK), and vimentin (Vim). The expression pattern of normal kidney was also examined and correlated with RENs. Although there is some overlap, subtypes of RENs show distinctive CK expression profiles that may be useful in several differential diagnostic settings. Clear cell RCCs typically showed a restricted expression pattern of CK8, CK18 and Vim. Papillary RCCs typically expressed CK7, CK8, CK18, CK19, and Vim and could be distinguished from MA (CK7-). Chromophobe RCCs were typically CK7+, CK8+, CK18+, and Vim-, and could be distinguished from oncocytomas (typically CK7-). In oncocytomas, nonspecific staining of unblocked endogenous biotin is a potentially significant diagnostic pitfall. CDC, RMC, and TC demonstrated similar CK expression profiles (with the exception of HMWCK expression limited to CDC), supporting a close relationship between these entities. A panel of CK5/CK6, CK17, and Vim may be helpful in distinguishing CDC (typically CK5/CK6-, CK17-, Vim+) and urothelial carcinoma (typically CK5/CK6+, CK17+, Vim-). In conclusion, CK expression patterns may be helpful in several differential diagnostic situations when dealing with adult RENs.
-
distribution of Cytokeratins and vimentin in adult renal neoplasms and normal renal tissue potential utility of a Cytokeratin Antibody panel in the differential diagnosis of renal tumors
The American Journal of Surgical Pathology, 2005Co-Authors: Brian Skinnider, Andrew L Folpe, Randolph A Hennigar, Cynthia Cohen, Pheroze Tamboli, Andrew T Young, Mariza De Peraltaventurina, Mahul B AminAbstract:Abstract:Adult renal epithelial neoplasms (RENs) comprise several distinct clinicopathologic entities with potential prognostic and therapeutic differences. Individual cases can show overlapping morphologic features, necessitating the use of ancillary methods. The purpose of this study was to determ
Sabine Kasimirbauer - One of the best experts on this subject based on the ideXlab platform.
-
does primary neoadjuvant systemic therapy eradicate minimal residual disease analysis of disseminated and circulating tumor cells before and after therapy
Breast Cancer Research, 2016Co-Authors: Sabine Kasimirbauer, Rainer Kimmig, Annkathrin Bittner, Lisa Konig, Katharina Reiter, Thomas Keller, Oliver HoffmannAbstract:Patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT) may experience metastatic relapse despite achieving a pathologic complete response. We analyzed patients with BC before and after NACT for disseminated tumor cells (DTCs) in the bone marrow(BM); comprehensively characterized circulating tumor cells (CTCs), including stem cell–like CTCs (slCTCs), in blood to prove the effectiveness of treatment on these cells; and correlated these findings with response to therapy, progression-free survival (PFS), and overall survival (OS). CTCs (n = 135) and slCTCs (n = 91) before and after NACT were analyzed using the AdnaTest BreastCancer, AdnaTest TumorStemCell, and epithelial–mesenchymal transition (QIAGEN Hannover GmbH Germany). The expression of estrogen receptor, progesterone receptor, and the resistance marker excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), nuclease were studied in separate single-plex reverse transcription polymerase chain reaction experiments. DTCs were evaluated in 142 patients before and 165 patients after NACT using the pan-Cytokeratin Antibody A45-B/B3 for immunocytochemistry. The positivity rates for DTCs, CTCs, and slCTCs were 27 %, 24 %, and 51 % before and 20 %, 8 %, and 20 % after NACT, respectively. Interestingly, 72 % of CTCs present after therapy were positive for ERCC1, and CTCs before (p = 0.005) and after NACT (p = 0.05) were significantly associated with the presence of slCTCs. Whereas no significant associations with clinical parameters were found for CTCs and slCTCs, DTCs were significantly associated with nodal status (p = 0.03) and histology (0.046) before NACT and with the immunohistochemical subtype (p = 0.02) after NACT. Univariable Cox regression analysis revealed that age (p = 0.0065), tumor size before NACT (p = 0.0473), nodal status after NACT (p = 0.0137), and response to NACT (p = 0.0136) were significantly correlated with PFS, whereas age (p = 0.0162) and nodal status after NACT (p = 0.0243) were significantly associated with OS. No significant correlations were found for DTCs or any CTCs before and after therapy with regard to PFS and OS. Although CTCs were eradicated more effectively than DTCs, CTCs detected after treatment seemed to be associated with tumor cells showing tumor stem cell characteristics as well as with resistant tumor cell populations that might indicate a worse outcome in the future. Thus, these patients might benefit from additional second-line treatment protocols including bisphosphonates for the eradication of DTCs.
-
expression of stem cell and epithelial mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
Breast Cancer Research, 2012Co-Authors: Sabine Kasimirbauer, Diethelm Wallwiener, Oliver Hoffmann, Rainer Kimmig, Tanja FehmAbstract:The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502 primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients. A total of 2 × 5 ml of blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [TWIST1, Akt2, phosphoinositide kinase-3 (PI3Kα)] and separately for the tumor stem cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-Cytokeratin Antibody A45-B/B3. Ninety-seven percent of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts, respectively. CTC were detected in 97/502 (19%) patients. At least one of the EMT markers was expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no correlation was found between BM status and CTC positivity (P = 0.41). The presence of CTC, EMT and ALDH1 expression was not correlated to any of the prognostic clinical markers. Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in a prospective trial.
-
detection and characterization of circulating tumor cells in blood of primary breast cancer patients by rt pcr and comparison to status of bone marrow disseminated cells
Breast Cancer Research, 2009Co-Authors: Tanja Fehm, Oliver Hoffmann, Bahriye Aktas, Sven Becker, E F Solomayer, Diethelm Wallwiener, Rainer Kimmig, Sabine KasimirbauerAbstract:The role of circulating tumor cells (CTCs) in blood of primary breast cancer patients is still under investigation. We evaluated the incidence of CTCs in blood, we evaluated the correlation between CTCs and disseminated tumor cells (DTCs) in the bone marrow (BM), and we characterized CTCs for the expression of HER2, the estrogen receptor (ER) and the progesterone receptor (PR). Blood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1 and HER2 transcripts with the AdnaTest BreastCancer™ (AdnaGen AG, Germany). Expression of the ER and PR was assessed in an additional RT-PCR. BM aspirates from 414 patients were analyzed for DTCs by immunocytochemistry using the pan-Cytokeratin Antibody A45-B/B3. DTCs were found in 107/414 patients (24%), CTCs were detected in 58/431 (13%) patients. DTCs were associated with PR status of the primary tumor (P = 0.04) and CTCs significantly correlated with nodal status (P = 0.04), ER (P = 0.05), and PR (P = 0.01). DTCs in the BM weakly correlated with CTCs (P = 0.05) in blood. Interestingly, the spread of CTCs was mostly found in triple-negative tumors (P = 0.01) and CTCs in general were mostly found to be triple-negative regardless of the ER, PR and HER2 status of the primary tumor. (1) Due to the weak concordance between CTCs and DTCs the clinical relevance may be different. (2) The biology of the primary tumor seems to direct the spread of CTCs. (3) Since the expression profile between CTCs and the primary tumor differs, the consequence for the selection of adjuvant treatment has to be evaluated.
Zhiwei Zhou - One of the best experts on this subject based on the ideXlab platform.
-
• BRIEF REPORTS • Detection of lymph nodes micrometastases in Dukes ’ A and B colorectal cancer using anti-Cytokeratin antibodies AE1/AE3
2015Co-Authors: Zhiwei Zhou, Nick Rieger, Andrew Ruszkiewicz, Guo Qiang Wang, De-sen WanAbstract:AIM: To detect lymph nodes micrometastases and analyze its correlation with clinicopathological parameters in Dukes’ A and B colorectal cancer patients. METHODS: One hundred and fourteen patients with colorectal cancer (Dukes ’ A 16; Dukes ’ B 98) undergoing curative operation without histological lymph nodes metastases were studied between 2001 and 2003. A total of 2 481 lymph nodes were analyzed using monoclonal Cytokeratin Antibody AE1/AE3 (DAKO, Carpinteria, CA) for immunohist-ochemistry. RESULTS: In total, 33 (29%) patients were positive for cancer cell by immunohistochemistry. In 31 (94%) patients of them positive nodes showed single tumor cell or small groups of tumor cells; and tumor deposits measuring 0.
-
detection of lymph nodes micrometastases in dukes a and b colorectal cancer using anti Cytokeratin antibodies ae1 ae3
World Journal of Gastroenterology, 2005Co-Authors: Zhiwei Zhou, Nick Rieger, Andrew Ruszkiewicz, Guo Qiang WangAbstract:AIM: To detect lymph nodes micrometastases and analyze its correlation with clinicopathological parameters in Dukes’ A and B colorectal cancer patients. METHODS: One hundred and fourteen patients with colorectal cancer (Dukes’ A 16; Dukes’ B 98) undergoing curative operation without histological lymph nodes metastases were studied between 2001 and 2003. A total of 2 481 lymph nodes were analyzed using monoclonal Cytokeratin Antibody AE1/AE3 (DAKO, Carpinteria, CA) for immunohist-ochemistry. RESULTS: In total, 33 (29%) patients were positive for cancer cell by immunohistochemistry. In 31 (94%) patients of them positive nodes showed single tumor cell or small groups of tumor cells; and tumor deposits measuring 0.2 and 0.37 mm in diameter in another 2 (6%) patients. Micrometastases were mainly located in the subcapsular sinus or paracortical sinus. There was no correlation between the positive lymph nodes and gender, age, tumor site, tumor size, histological type, histological grade, invasion depth, Dukes’ staging and microsatellite instability (P>0.05). CONCLUSION: Our findings suggest that immunohist-ochemical technique using monoclonal Cytokeratin Antibody AE1/AE3 may be a sensitive and reliable method for detecting lymph nodes micrometastases in Dukes’ A and B colorectal cancer. The clinical significance of lymph nodes microme-tastases is still not confirmed.
